Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Identifieur interne : 001943 ( Istex/Corpus ); précédent : 001942; suivant : 001944Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Auteurs : Judit Horvath ; Robin D. Fross ; Galit Kleiner-Fisman ; René Lerch ; Hans Stalder ; Suzanne Liaudat ; William J. Raskoff ; Keith D. Flachsbart ; Harry Rakowski ; Jean-Claude Pache ; Pierre R. Burkhard ; Anthony E. LangSource :
- Movement Disorders [ 0885-3185 ] ; 2004-06.
English descriptors
- KwdEn :
Abstract
We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti‐migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin‐mediated abnormal fibrogenesis by means of the 5‐HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot‐derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20201
Links to Exploration step
ISTEX:AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title><author><name sortKey="Horvath, Judit" sort="Horvath, Judit" uniqKey="Horvath J" first="Judit" last="Horvath">Judit Horvath</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Fross, Robin D" sort="Fross, Robin D" uniqKey="Fross R" first="Robin D." last="Fross">Robin D. Fross</name><affiliation><mods:affiliation>Department of Neurology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Kleiner Isman, Galit" sort="Kleiner Isman, Galit" uniqKey="Kleiner Isman G" first="Galit" last="Kleiner-Fisman">Galit Kleiner-Fisman</name><affiliation><mods:affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Lerch, Rene" sort="Lerch, Rene" uniqKey="Lerch R" first="René" last="Lerch">René Lerch</name><affiliation><mods:affiliation>Division of Cardiology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Stalder, Hans" sort="Stalder, Hans" uniqKey="Stalder H" first="Hans" last="Stalder">Hans Stalder</name><affiliation><mods:affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Liaudat, Suzanne" sort="Liaudat, Suzanne" uniqKey="Liaudat S" first="Suzanne" last="Liaudat">Suzanne Liaudat</name><affiliation><mods:affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Raskoff, William J" sort="Raskoff, William J" uniqKey="Raskoff W" first="William J." last="Raskoff">William J. Raskoff</name><affiliation><mods:affiliation>Department of Cardiology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Flachsbart, Keith D" sort="Flachsbart, Keith D" uniqKey="Flachsbart K" first="Keith D." last="Flachsbart">Keith D. Flachsbart</name><affiliation><mods:affiliation>Department of Cardiovascular Surgery, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Rakowski, Harry" sort="Rakowski, Harry" uniqKey="Rakowski H" first="Harry" last="Rakowski">Harry Rakowski</name><affiliation><mods:affiliation>Divisions of Neurology and Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Pache, Jean Laude" sort="Pache, Jean Laude" uniqKey="Pache J" first="Jean-Claude" last="Pache">Jean-Claude Pache</name><affiliation><mods:affiliation>Department of Pathology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Burkhard, Pierre R" sort="Burkhard, Pierre R" uniqKey="Burkhard P" first="Pierre R." last="Burkhard">Pierre R. Burkhard</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20201</idno><idno type="url">https://api.istex.fr/document/AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001943</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title><author><name sortKey="Horvath, Judit" sort="Horvath, Judit" uniqKey="Horvath J" first="Judit" last="Horvath">Judit Horvath</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Fross, Robin D" sort="Fross, Robin D" uniqKey="Fross R" first="Robin D." last="Fross">Robin D. Fross</name><affiliation><mods:affiliation>Department of Neurology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Kleiner Isman, Galit" sort="Kleiner Isman, Galit" uniqKey="Kleiner Isman G" first="Galit" last="Kleiner-Fisman">Galit Kleiner-Fisman</name><affiliation><mods:affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Lerch, Rene" sort="Lerch, Rene" uniqKey="Lerch R" first="René" last="Lerch">René Lerch</name><affiliation><mods:affiliation>Division of Cardiology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Stalder, Hans" sort="Stalder, Hans" uniqKey="Stalder H" first="Hans" last="Stalder">Hans Stalder</name><affiliation><mods:affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Liaudat, Suzanne" sort="Liaudat, Suzanne" uniqKey="Liaudat S" first="Suzanne" last="Liaudat">Suzanne Liaudat</name><affiliation><mods:affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Raskoff, William J" sort="Raskoff, William J" uniqKey="Raskoff W" first="William J." last="Raskoff">William J. Raskoff</name><affiliation><mods:affiliation>Department of Cardiology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Flachsbart, Keith D" sort="Flachsbart, Keith D" uniqKey="Flachsbart K" first="Keith D." last="Flachsbart">Keith D. Flachsbart</name><affiliation><mods:affiliation>Department of Cardiovascular Surgery, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Rakowski, Harry" sort="Rakowski, Harry" uniqKey="Rakowski H" first="Harry" last="Rakowski">Harry Rakowski</name><affiliation><mods:affiliation>Divisions of Neurology and Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Pache, Jean Laude" sort="Pache, Jean Laude" uniqKey="Pache J" first="Jean-Claude" last="Pache">Jean-Claude Pache</name><affiliation><mods:affiliation>Department of Pathology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Burkhard, Pierre R" sort="Burkhard, Pierre R" uniqKey="Burkhard P" first="Pierre R." last="Burkhard">Pierre R. Burkhard</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-06">2004-06</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="656">656</biblScope><biblScope unit="page" to="662">662</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760</idno><idno type="DOI">10.1002/mds.20201</idno><idno type="ArticleID">MDS20201</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cabergoline</term><term>ergot‐derived dopamine agonists</term><term>heart</term><term>pergolide</term><term>valvulopathy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti‐migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin‐mediated abnormal fibrogenesis by means of the 5‐HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot‐derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Judit Horvath MD</name><affiliations><json:string>Department of Neurology, University Hospital, Geneva, Switzerland</json:string></affiliations></json:item><json:item><name>Robin D. Fross MD</name><affiliations><json:string>Department of Neurology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</json:string></affiliations></json:item><json:item><name>Galit Kleiner‐Fisman MD</name><affiliations><json:string>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</json:string></affiliations></json:item><json:item><name>René Lerch MD</name><affiliations><json:string>Division of Cardiology, University Hospital, Geneva, Switzerland</json:string></affiliations></json:item><json:item><name>Hans Stalder MD</name><affiliations><json:string>Department of Community Medicine, University Hospital, Geneva, Switzerland</json:string></affiliations></json:item><json:item><name>Suzanne Liaudat MD</name><affiliations><json:string>Department of Community Medicine, University Hospital, Geneva, Switzerland</json:string></affiliations></json:item><json:item><name>William J. Raskoff MD</name><affiliations><json:string>Department of Cardiology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</json:string></affiliations></json:item><json:item><name>Keith D. Flachsbart MD</name><affiliations><json:string>Department of Cardiovascular Surgery, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</json:string></affiliations></json:item><json:item><name>Harry Rakowski MD</name><affiliations><json:string>Divisions of Neurology and Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Jean‐Claude Pache MD</name><affiliations><json:string>Department of Pathology, University Hospital, Geneva, Switzerland</json:string></affiliations></json:item><json:item><name>Pierre R. Burkhard MD</name><affiliations><json:string>Department of Neurology, University Hospital, Geneva, Switzerland</json:string></affiliations></json:item><json:item><name>Anthony E. Lang MD</name><affiliations><json:string>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>heart</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>valvulopathy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ergot‐derived dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pergolide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cabergoline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti‐migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin‐mediated abnormal fibrogenesis by means of the 5‐HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot‐derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>5.89</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1448</abstractCharCount><pdfWordCount>3370</pdfWordCount><pdfCharCount>22621</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>210</abstractWordCount></qualityIndicators><title>Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>7</total><last>662</last><first>656</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20201</json:string></doi><id>AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title><author><persName><forename type="first">Judit</forename><surname>Horvath</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</affiliation></author><author><persName><forename type="first">Robin D.</forename><surname>Fross</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</affiliation></author><author><persName><forename type="first">Galit</forename><surname>Kleiner‐Fisman</surname><roleName type="degree">MD</roleName></persName><affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</affiliation></author><author><persName><forename type="first">René</forename><surname>Lerch</surname><roleName type="degree">MD</roleName></persName><affiliation>Division of Cardiology, University Hospital, Geneva, Switzerland</affiliation></author><author><persName><forename type="first">Hans</forename><surname>Stalder</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</affiliation></author><author><persName><forename type="first">Suzanne</forename><surname>Liaudat</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</affiliation></author><author><persName><forename type="first">William J.</forename><surname>Raskoff</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Cardiology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</affiliation></author><author><persName><forename type="first">Keith D.</forename><surname>Flachsbart</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Cardiovascular Surgery, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</affiliation></author><author><persName><forename type="first">Harry</forename><surname>Rakowski</surname><roleName type="degree">MD</roleName></persName><affiliation>Divisions of Neurology and Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</affiliation></author><author><persName><forename type="first">Jean‐Claude</forename><surname>Pache</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Pathology, University Hospital, Geneva, Switzerland</affiliation></author><author><persName><forename type="first">Pierre R.</forename><surname>Burkhard</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, University Hospital – HUG, 24, rue Micheli‐du‐Crest, 1211 Geneva 14, Switzerland</p></note><affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</affiliation></author><author><persName><forename type="first">Anthony E.</forename><surname>Lang</surname><roleName type="degree">MD</roleName></persName><affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-06"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="656">656</biblScope><biblScope unit="page" to="662">662</biblScope></imprint></monogr><idno type="istex">AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760</idno><idno type="DOI">10.1002/mds.20201</idno><idno type="ArticleID">MDS20201</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti‐migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin‐mediated abnormal fibrogenesis by means of the 5‐HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot‐derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>heart</term></item><item><term>valvulopathy</term></item><item><term>ergot‐derived dopamine agonists</term></item><item><term>pergolide</term></item><item><term>cabergoline</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-01-21">Received</change><change when="2004-02-01">Registration</change><change when="2004-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v19:6</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2004-06">June 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="70" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20201</doi><idGroup><id type="unit" value="MDS20201"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-01-21"></event><event type="manuscriptAccepted" date="2004-02-01"></event><event type="publishedOnlineEarlyUnpaginated" date="2004-05-21"></event><event type="firstOnline" date="2004-05-21"></event><event type="publishedOnlineFinalForm" date="2004-06-03"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">656</numbering><numbering type="pageLast">662</numbering></numberingGroup><correspondenceTo>Department of Neurology, University Hospital – HUG, 24, rue Micheli‐du‐Crest, 1211 Geneva 14, Switzerland</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20201.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="3745"></count></countGroup><titleGroup><title type="main" xml:lang="en">Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title><title type="short" xml:lang="en">Dopamine Agonists and Valvulopathy</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Judit</givenNames><familyName>Horvath</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Robin D.</givenNames><familyName>Fross</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Galit</givenNames><familyName>Kleiner‐Fisman</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>René</givenNames><familyName>Lerch</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Hans</givenNames><familyName>Stalder</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Suzanne</givenNames><familyName>Liaudat</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>William J.</givenNames><familyName>Raskoff</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Keith D.</givenNames><familyName>Flachsbart</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Harry</givenNames><familyName>Rakowski</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Jean‐Claude</givenNames><familyName>Pache</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Pierre R.</givenNames><familyName>Burkhard</familyName><degrees>MD</degrees></personName><contactDetails><email>pierre.burkhard@hcuge.ch</email></contactDetails></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CH" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Geneva, Switzerland</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CA" type="organization"><unparsedAffiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="CH" type="organization"><unparsedAffiliation>Division of Cardiology, University Hospital, Geneva, Switzerland</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="CH" type="organization"><unparsedAffiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Cardiology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Cardiovascular Surgery, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="CA" type="organization"><unparsedAffiliation>Divisions of Neurology and Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="CH" type="organization"><unparsedAffiliation>Department of Pathology, University Hospital, Geneva, Switzerland</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">heart</keyword><keyword xml:id="kwd2">valvulopathy</keyword><keyword xml:id="kwd3">ergot‐derived dopamine agonists</keyword><keyword xml:id="kwd4">pergolide</keyword><keyword xml:id="kwd5">cabergoline</keyword><keyword xml:id="kwd6">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti‐migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin‐mediated abnormal fibrogenesis by means of the 5‐HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot‐derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Dopamine Agonists and Valvulopathy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists</title></titleInfo><name type="personal"><namePart type="given">Judit</namePart><namePart type="family">Horvath</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robin D.</namePart><namePart type="family">Fross</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Galit</namePart><namePart type="family">Kleiner‐Fisman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">René</namePart><namePart type="family">Lerch</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Cardiology, University Hospital, Geneva, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hans</namePart><namePart type="family">Stalder</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Suzanne</namePart><namePart type="family">Liaudat</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Community Medicine, University Hospital, Geneva, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William J.</namePart><namePart type="family">Raskoff</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Cardiology, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Keith D.</namePart><namePart type="family">Flachsbart</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Cardiovascular Surgery, Kaiser Permanente Medical Centers, Hayward and San Francisco, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Harry</namePart><namePart type="family">Rakowski</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Divisions of Neurology and Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Claude</namePart><namePart type="family">Pache</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Pathology, University Hospital, Geneva, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre R.</namePart><namePart type="family">Burkhard</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Geneva, Switzerland</affiliation><description>Correspondence: Department of Neurology, University Hospital – HUG, 24, rue Micheli‐du‐Crest, 1211 Geneva 14, Switzerland</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Centers, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-06</dateIssued><dateCaptured encoding="w3cdtf">2004-01-21</dateCaptured><dateValid encoding="w3cdtf">2004-02-01</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">1</extent><extent unit="references">17</extent><extent unit="words">3745</extent></physicalDescription><abstract lang="en">We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti‐migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin‐mediated abnormal fibrogenesis by means of the 5‐HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot‐derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists. © 2004 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>heart</topic><topic>valvulopathy</topic><topic>ergot‐derived dopamine agonists</topic><topic>pergolide</topic><topic>cabergoline</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>656</start><end>662</end><total>7</total></extent></part></relatedItem><identifier type="istex">AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760</identifier><identifier type="DOI">10.1002/mds.20201</identifier><identifier type="ArticleID">MDS20201</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001943 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001943 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:AF295CD0EDF6A2AB1371847C1780B0CF9F8FD760
|texte= Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
}}
| This area was generated with Dilib version V0.6.23. |  |